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Pain scaleAbstract Aim of the work: This study aimed to assess the efﬁcacy of ultrasound-guided versus
palpation-guided local corticosteroid injection therapy for the treatment of plantar fasciitis (PF).
Patients and methods: The present study included 21 female patients with unilateral chronic idio-
pathic PF. The study included 10 female healthy volunteers (20 feet) as a control group. The par-
ticipants were randomly assigned to receive ultrasound-guided (10 patients) or palpation-guided
(11 patients) local corticosteroid injection once. The corticosteroid drug was 0.5 ml of triamcinolone
acetonide (40 mg/ml). Patients were evaluated before injection and 2 weeks and 4 weeks following
injection. Clinical evaluation was done by using the visual analog scale (VAS) for heel pain assess-
ment and Plantar Fasciitis Pain/Disability Scale. Ultrasonographic evaluation was done by assess-
ing plantar fascia thickness and echogenicity.
Results: There was a statistically signiﬁcant reduction in VAS, Plantar Fasciitis Pain/Disability
Scale, plantar fascia thickness and improvement in plantar fascia echogenicity after treatment in
both patient groups; however, there were no statistically signiﬁcant differences between both
groups. The plantar fascia thickness was statistically signiﬁcantly thicker in both groups in relation
to control group before injection and after it by 2 weeks and 4 weeks. The plantar fascia hypoe-
chogenicity was found exclusively among patients groups before injection. At 4 weeks after injec-
tion, the hypoechogenicity disappeared in all patients of both groups.
Conclusions: Ultrasound-guided and palpation-guided local corticosteroid injections were effec-
tive and successful in treatment of PF. Both techniques improved PF clinically and ultrasonograph-
ically without statistically signiﬁcant superior results for the ultrasound-guided injection.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The plantar fascia is susceptible to repetitive microtrauma at
its posterior attachment at the calcaneus [1]. This leads to
the development of plantar fasciitis (PF) [2]. PF is the most
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However, idiopathic PF is due to repetitive degenerative lesion
to the enthesis of plantar fascia, it can be a result of inﬂamma-
tory enthesopathy [1,4]. The clinical diagnosis of PF can be
made easily on clinical basis. Imaging can help in the diagnosis
of PF. It is recommended in chronic refractory cases for
conﬁrmation of the diagnosis [5]. Ultrasonography is the
commonest method of radiological assessment [5,6].
Conservative therapy for PF is the standardized manage-
ment. It is agreed that it is effective in approximately 90–
95% of patients [3,7,8]. When conservative treatment fails,
minimally invasive techniques such as corticosteroid injection
may be used for the management of PF [2,9–11]. Local corti-
costeroid injection for PF can be performed by many methods.
It can be palpation-guided injection, ultrasonographic-guided
injection and scintigraphic-guided injection. Palpation-guided
injection is the approach traditionally used [12,13].
The aim of the current study was to prospectively assess the
efﬁcacy of ultrasound (US)-guided versus palpation-guided
local corticosteroid injection on the clinical and ultrasono-
graphical responses in patients with chronic idiopathic PF.
2. Patients and methods
2.1. Patients
The present prospective study included 21 consecutive patients
with unilateral chronic idiopathic PF. The patients were
recruited sequentially from those attending the outpatient
clinic of Physical Medicine, Rheumatology and
Rehabilitation Department, Main University Hospital,
Alexandria Faculty of Medicine between May 2013 and
January 2015. A control group of 10 apparently healthy volun-
teers were included. The volunteers consisted of medical staff,
their relatives and patients’ relatives. Clinical diagnosis of PF
was based on the presence of the following: (i) the presence
of post-static dyskinesia; (ii) the presence of heel pain as sharp,
shooting or dull aching pain made worse in postures with
weight bearing such as in standing and walking; and the occur-
rence of pain with rest and in non-weight bearing positions was
also included; and (iii) the presence of localized tenderness in
and around the medial calcaneal tuberosity at proximal plan-
tar fascia on physical examination [2,14,15]. All patients were
unresponsive to conservative treatment for at least 3 months to
be considered chronic PF. The conservative treatment included
rest, non-steroidal anti-inﬂammatory drugs, activity modiﬁca-
tion, shoe modiﬁcation, prefabricated inserts, orthosis, stretch-
ing exercises, ultrasound diathermy, transcutaneous electrical
nerve stimulation and extracorporeal shock wave therapy
[3,7,8,15]. The study was explained to the participants and
an informed consent was given by each. The study had been
approved by the local Institutional ethics committee of the
Faculty of Medicine, Alexandria University, Egypt.
Patients were excluded from the study if they had received a
previous corticosteroid injection for PF, or if they had any of
the following: a known hypersensitivity to corticosteroids, cur-
rent pregnancy, current skin or soft tissue infection at or near
the injection site, heel fat pad atrophy, posterior heel pain,
rheumatologic disorders, endocrine disorders, metabolic disor-
ders, peripheral arterial insufﬁciency in the lower limbs,previous local surgery, or a history of local heel trauma and
neurological disorders as peripheral neuropathy or tarsal tun-
nel syndrome [16]. Patients with a diagnosis of bilateral PF
were also not enrolled in the study to exclude any potential sys-
temic disease [4].
2.2. Methods
Demographic data collection and assessment of pain severity
were done by using visual analog scale (VAS) [17]. The PF pain
severity and impact on functional status were assessed using
Plantar Fasciitis Pain/Disability Scale which consisted of two
components one for pain and the other for functional abilities,
in which the higher the score the worse is the condition and
vice versa [18]. Measurement of anthropometric measures
was done for all patients and control subjects. Body mass
index (BMI) was calculated as weight (kg)/[height (m)]2 [19].
Patients were evaluated clinically and radiologically.
Clinical evaluation involved tenderness around the medial cal-
caneal tuberosity or proximal plantar fascia [14,15]. All
patients were evaluated by plain radiography of the heel (lat-
eral view) for detecting the presence of calcaneal spur or any
pre-existing foot lesions. Sonographic evaluation assessed the
thickness of the proximal part of plantar fascia and its
echogenicity.
The patients were randomly assigned to either US-guided
or palpation-guided injection groups [US group and palpation
(PAL) group respectively]. Local corticosteroid injection was
done using 0.5 ml (20 mg) of triamcinolone acetonide suspen-
sion. All injections were performed by the same investigator
(the ﬁrst researcher). Any ongoing medical treatment or phys-
iotherapy was stopped before starting the injection therapy.
The initial baseline clinical and sonographic assessments
were done before injection (preinjection assessment).
Reassessment of all patients was done clinically and sono-
graphically after injection by 2 weeks and again by 4 weeks
(postinjection assessments). Searching for side effects of local
corticosteroid injection and recurrence of symptoms were done
in each postinjection assessment visit.
Real-time ultrasonographic examination of all patients at
all time points was performed by the same sonographer (the
second investigator). The examination was performed using a
10 MHz linear array transducer [Sonoline G 20 (model num-
ber: MC-12H613-ME), Siemens, Japan]. Patients were placed
in a prone position with the feet hanging over the edge of
the examination table, with dorsiﬂexion of the toes to stretch
the plantar fascia so that its margins were seen clearly.
Longitudinal sonographic images of plantar fascia were
obtained. The sonographic diagnosis was based on the pres-
ence of plantar fascial thickening of greater than the reference
cut-off value obtained from the control group, fusiform thick-
ening of the plantar fascia close to the calcaneal enthesis and
an abnormal fascial echo texture. The thickness of the plantar
fascia was measured at its proximal end near its insertion to
the calcaneus at its thickest portion. The presence of focal or
diffuse changes in fascial echogenicity was recorded as hyper-
echoic or hypoechoic [20].
The injection area was sterilized with povidone-iodine
solution. Injection was done through an aseptic technique to
minimize infection risk. A 22-gauge needle connected to a
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tonide suspension was prepared. Patients were placed in a
prone position with the ankle in a neutral position.
Ultrasonographic-guided local corticosteroid injection was
done for the US group. Under real-time sonographic guidance,
injection was done by a medial approach. It was performed
according to the technique described by Kane et al. [21].
Palpation-guided local corticosteroid injection was done for
the PAL group. Injection was done by a medial approach,
through the maximally tender spot on the plantar surface of
the heel. It was performed according to the technique
described by Jacobs [22]. Injection into the heel pad of fat
was avoided.
All patients were instructed to reduce weight bearing on the
affected heel for 2 days, with a subsequent increase in ambula-
tion over the next few days, and to avoid all running and other
high impact activities for at least 1 week. Advice for wearing
comfortable shoes was given to all patients [2].
Outcome measures were assessed in the two follow-up visits
which included: (i) clinical assessment of pain and functional
status using VAS and Plantar Fasciitis Pain/Disability Scale
and the presence of tenderness on palpation of the medial cal-
caneal tuberosity or proximal plantar fascia on physical exam-
ination; (ii) ultrasonographic assessment of plantar fascia
thickness and echogenicity.
According to the ﬁndings of the outcome measures in the
last postinjection assessment (4 week postinjection) visit, the
patients were categorized as having the following:
(I) Complete remission, the patient had no pain, no restric-
tion of function and no tenderness on palpation (com-
plete clinical remission); and plantar fascia thickness
less than the cut-off value obtained from control sub-
jects and normal echogenicity of the plantar fascia (com-
plete ultrasonographic remission).
(II) Partial remission, the patient had improvement of more
than 50% in pain and restriction of function with or
without the presence of tenderness on palpation (partial
clinical remission); and decreased thickness of plantar
fascia in relation to the preinjection thickness, although,
it is still thicker than the cut-off value of plantar fascia
thickness obtained from the control subjects and/or
hypoechogenicity of the plantar fascia (partial ultra-
sonographic remission).
Statistical analysis of data was done by using the Statistical
Package of Social Science (SPSS version 17) software.
Descriptive measures [count, frequency, minimum, maximum,
median, mean and standard deviation (SD)] were used.
Analytic measures included: (i) qualitative data were analyzed
using Chi-square test or Fisher’s Exact test (when required),
McNemar test and Cochran’s Q test; and (ii) quantitative data
were analyzed using Mann Whitney test, Kruskel–Wallis test,
Wilcoxon Signed Ranks test and Friedman test. Statistical sig-
niﬁcance was assigned to any P value at 60.05. The reference
cut-off value of the plantar fascia thickness was calculated by
rounding the mean plus two SD to measure the upper limit of
normal. The sensitivity was calculated as the number of feet
with a positive ultrasonographic evidence of PF and clinical
evidence of PF at preinjection evaluation/total number of feet
with clinical evidence of PF at preinjection evaluation. The
speciﬁcity was calculated as the number of feet of healthycontrol subjects with a normal ultrasonographic evaluation/to-
tal number of all feet of healthy subjects (control group).
Positive predictive value was calculated as the number of PF
feet with a positive ultrasonographic examination at preinjec-
tion evaluation/total number of PF feet and control feet with
positive ultrasonographic examination at preinjection evalua-
tion. Negative predictive value was calculated as the number
of control feet with a negative ultrasonographic examination/
total number of PF feet and control feet with negative ultra-
sonographic examination at preinjection evaluation.3. Results
The present study included 21 female patients with unilateral
chronic idiopathic PF. They were divided randomly into two
treatment groups. First group constituted of 10 patients
(47.62%) who had US-guided injection (US group). Second
group constituted of 11 patients (52.38%) who had
palpation-guided injection (PAL group). The study included
10 female healthy volunteers (20 feet) as a control group.
There were no statistically signiﬁcance differences between
the three groups as regards age and BMI (K= 0.244,
P= 0.885; K= 1.324, P=0.516, respectively). The demo-
graphic and clinical features of the patients and control
subjects are summarized in Table 1. All patients had calcaneal
spur in their plain X-ray heel.
There was no patient withdrawal from the study and no
patients lost to follow-up. There were no drug side effects
reported by the patients of either group in the 2 week or 4 week
postinjection follow-up visits.
There were no statistically signiﬁcant differences between
the US group and PAL group as regards the subjective assess-
ment in the baseline and the two postinjection follow-up visits
as regards pain severity assessment by using VAS and the pain
component of Plantar Fasciitis Pain/Disability Scale, and
functional assessment by using the functional component of
Plantar Fasciitis Pain/Disability Scale (P> 0.05). However,
there was a statistically signiﬁcant improvement in the subjec-
tively assessed parameters among the two treatment groups
when the ﬁndings of the 2 week and 4 week postinjection visits
were compared to the preinjection assessment (P< 0.0001). In
addition, there was a further statistically signiﬁcant improve-
ment in the subjectively assessed parameters among the two
treatment groups when the ﬁndings of the 4 week postinjection
visit were compared to the 2 week postinjection visit
(P< 0.05). Comparison between the two treatment groups
as regards the pain severity assessment by using VAS and
the total score of Plantar Fasciitis Pain/Disability Scale and
between the preinjection and the postinjection visits within
each treatment group is tabulated in Table 2.
The comparison between the two treatment groups and
control group as regards the plantar fascia thickness and
echogenicity assessed ultrasonographically and between the
preinjection and the postinjection visits within each treatment
group is tabulated in Tables 3 and 4. The cut-off value for
plantar fascia thickness was 4.1 mm as obtained from the con-
trol group. All control subjects (100%) had plantar fascia
thickness less than the cut-off value. All patients (100%) of
both treatment groups had plantar fascia thicker than the
cut-off value obtained from the control group in the preinjec-
tion visit. At 4 week postinjection follow-up, there was one
Table 1 Demographic data and clinical features of the two treatment groups and control group.
Clinical features US group (n= 10 feet
from 10 patients)
PAL group (n= 11 feet
from 11 patients)
Control group (n= 20 feet from 10
healthy volunteers)
Test of
signiﬁcance§
P
Age (year) 40 (45.20 ± 11.75) 46 (46.45 ± 8.84) 45.5 (45.90 ± 7.55) 0.244 0.885
Weight (kg) 92.50 (92.45 ± 6.89) 96.00 (91.27 ± 14.81) 91.50 (89.50 ± 11.72) 0.349 0.840
Height (cm) 160.25 (159.40 ± 3.57) 161.00 (158.45 ± 6.23) 160.50 (160.80 ± 7.49) 0.278 0.870
BMI (kg/m2) 36.60 (36.37 ± 2.55) 36.50 (36.45 ± 6.05) 34.50 (34.79 ± 5.31) 1.856 0.395
BMI categories
Normal weight 0 (0) 1 (9.1) 0 (0) 5.942 0.430
Overweight 1 (10) 0 (0) 2 (20)
Obesity 8 (80) 8 (72.7) 6 (60)
Morbid obesity 1 (10) 2 (18.2) 2 (20)
Occupation (housewife/
employed)
6/4 (60/40) 7/4 (63.6/36.4) 10/10 (50/50) 0.618 0.734
Side (right/left) 6/4 (60/40) 5/6 (45.5/54.5) 10/10 (50/50) 0.467 0.792
Duration of the
condition (months)
14.00 (25.20 ± 23.21) 15.00 (24.54 ± 22.24) NA 0.071 0.943
US group, ultrasound group; PAL group, palpation group; kg, kilogram; cm, centimeter; BMI, body mass index; n, number of feet; NA, not
applicable.
*P is signiﬁcant at 60.05.
 Data are reported as median (mean ± standard deviation).
 Data are reported as number (percentage).
§ Value of the test of signiﬁcance (Kruskel–Wallis test and Chi-square test) used for comparing between the two treatment groups and control
group while (Mann–Whitney test) used for comparing between the two treatment groups regarding the duration of the condition.
Table 2 Comparison between the two treatment groups as regards the patient assessment of pain severity using visual analog scale
and the Plantar Fasciitis Pain/Disability Scale and between the preinjection and the postinjection visits within each treatment group.
Treatment groups Preinjection visit 2 week postinjection follow-up visit 4 week postinjection follow-up visit P
Pain severity assessment by visual analog scale
US group (n= 10 patients) 90 (87.50 ± 12.30)§ 40 (33.00 ± 19.46)§,|| 10 (7.00 ± 6.74)|| <0.0001*
PAL group (n = 11 patients) 90 (86.36 ± 10.26)– 30 (31.81 ± 21.36)–,** 10 (9.54 ± 10.11)** <0.0001*
P 0.742 0.913 0.681 NA
Plantar Fasciitis Pain/Disability Scale
US group (n= 10 patients) 78.52 (76.92 ± 6.11)§ 19.81 (17.47 ± 11.09)§,|| 4.80 (4.24 ± 4.18)|| <0.0001*
PAL group (n= 11 patients) 76.84 (75.80 ± 3.93)– 20.41 (18.01 ± 11.36)–,** 5 (5.05 ± 5.12)** <0.0001*
P 0.379 0.944 0.719 NA
US group, ultrasound group; PAL group, palpation group; NA, not applicable.
Data are reported as median (mean ± standard deviation).
* P is signiﬁcant at 60.05.
 P-values are for test of signiﬁcance comparing between more than two dependent variables within the same treatment group using Friedman
test.
 P-values for test of signiﬁcance comparing the two treatment groups using Mann–Whitney test at each assessment visit.
§ Signiﬁcant difference (Wilcoxon Signed Ranks test) between preinjection visit and the 2 weeks postinjection follow-up visit in US group
(P< 0.05).
|| Signiﬁcant difference (Wilcoxon Signed Ranks test) between 2 weeks postinjection follow-up visit and the 4 weeks postinjection follow-up
visit in US group (P< 0.05).
– Signiﬁcant difference (Wilcoxon Signed Ranks test) between preinjection visit and the 2 weeks postinjection follow-up visit in PAL group
(P< 0.05).
** Signiﬁcant difference (Wilcoxon Signed Ranks test) between 2 weeks postinjection follow-up visit and the 4 weeks postinjection follow-up
visit in PAL group (P< 0.05).
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among the PAL group had thicker plantar fascia than the ref-
erence value. The presence of plantar fascia hypoechogenicity
was found exclusively among the patient groups in the prein-
jection assessment. At the 4 week postinjection follow-up visit,
the hypoechogenicity of plantar fascia disappeared in all
patients of both treatment groups.Fig. 1 is an illustration of the ultrasonographic image of a
healthy volunteer in comparison to that of a patient with PF at
the preinjection visit and 4 week postinjection follow-up visit.
At follow-up period of 4 weeks, all patients (100%) of both
treatment groups showed improvement in the Plantar Fasciitis
Pain/Disability Scale, disappearance of tenderness on palpa-
tion of the medial calcaneal tuberosity or proximal plantar
Table 3 Comparison between the two treatment groups and control group as regards the plantar fascia thickness assessed
ultrasonographically and between the preinjection and the postinjection visits within each treatment group.
Treatment groups Preinjection visit 2 weeks postinjection follow-up visit 4 weeks postinjection follow-up visit P
Plantar fascia thickness assessed ultrasonographically
US group (n= 10 feet) 5.20 (5.55 ± 0.62)k, 4.75 (4.66 ± 0.69)k,–,§§ 3.80 (3.85 ± 0.38)–,kk <0.0001*
PAL group (n= 11 feet) 5.10
(5.20 ± 0.65)**,
4.20 (4.15 ± 0.64)**,,§§ 3.90 (3.82 ± 0.41),kk <0.0001*
Control group (n= 20 feet) 3.15 (3.11 ± 0.51) 3.15 (3.11 ± 0.51) 3.15 (3.11 ± 0.51) NA
P§ 60.0001* 60.0001* 60.0001* NA
US group, ultrasound group; PAL group, palpation group; NA, not applicable.
Data are reported as median (mean ± standard deviation).
* P is signiﬁcant at 60.05.
 The reading of the control group was assessed once only.
 P-values are for test of signiﬁcance comparing between more than two dependent variables within the same treatment group using Friedman
test.
§ P-values for test of signiﬁcance comparing the three groups (two treatment groups and control group) using Kruskel–Wallis test at each
assessment visit.
k Signiﬁcant difference (Wilcoxon Signed Ranks test) between preinjection visit and the 2 week postinjection follow-up visit in US group
(P= 0.005).
– Signiﬁcant difference (Wilcoxon Signed Ranks test) between 2 week postinjection follow-up visit and the 4 week postinjection follow-up visit
in US group (P= 0.008).
** Signiﬁcant difference (Wilcoxon Signed Ranks test) between preinjection visit and the 2 week postinjection follow-up visit in PAL group
(P= 0.003).
 Signiﬁcant difference (Wilcoxon Signed Ranks test) between 2 week postinjection follow-up visit and the 4 week postinjection follow-up visit
in PAL group (P= 0.011).
 No signiﬁcant difference (Mann–Whitney test) between US group and PAL group (P= 0.216) at the preinjection visit.
§§ No signiﬁcant difference (Mann–Whitney test) between US group and PAL group (P= 0.105) at the 2 week postinjection follow-up visit.
kk No signiﬁcant difference (Mann–Whitney test) between US group and PAL group (P= 0.943) at the 4 week postinjection follow-up visit.
Table 4 Comparison between the two treatment groups and control group as regards the plantar fascia echogenicity assessed
ultrasonographically and between the preinjection and the postinjection visits within each treatment group.
Treatment groups Preinjection visit 2 week postinjection follow-up visit 4 week postinjection follow-up visit P
Plantar fascia echogenicity assessed ultrasonographically
US group (n= 10 feet) 2/8 (20/80)k, 9/1 (90/10)k,–,§§ 10/0 (100/0)– <0.0001*
PAL group (n= 11 feet) 1/10 (9.1/90.9)**, 8/3 (72.7/27.3)**,
,§§ 11/0 (100/0) <0.0001*
Control group (n= 20 feet) 20/0 (100/0) 20/0 (100/0) 20/0 (100/0) NA
P§ 60.0001* 0.050* NA NA
US group, ultrasound group; PAL group, palpation group.
Data are reported as [number/number (percentage/percentage)], the ﬁrst number and percentage indicate normal echogenicity while the second
number and percentage indicate hypoechogenicity.
* P is signiﬁcant at 60.05.
 The reading of the control group was assessed once only.
 P-values are for test of signiﬁcance comparing between more than two dependent variable within the same treatment group using Cochran’s Q
test.
§ P-values for test of signiﬁcance comparing the three groups (two treatment groups and control group) using Chi-square test at each assessment
visit.
k Signiﬁcant difference (McNemar test) between preinjection visit and 2 week postinjection follow-up visit in US group (P= 0.016).
– No signiﬁcant difference (McNemar test) between 2 week postinjection follow-up visit and the 4 week postinjection follow-up visit in US
group (P= 0.996).
** Signiﬁcant difference (McNemar test) between preinjection visit and 2 week postinjection follow-up visit in PAL group (P= 0.016).
 No signiﬁcant difference (McNemar test) between 2 week postinjection follow-up visit and the 4 week postinjection follow-up visit in PAL
group (P= 0.250).
 No signiﬁcant difference (Chi-Square test) between US group and PAL group (P= 0.476) at the preinjection visit.
§§ No signiﬁcant difference (Chi-Square test) between US group and PAL group (P= 0.314) at the 2 week postinjection follow-up visit.
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echogenicity of plantar fascia ultrasonographically. However,
there were no statistically signiﬁcant differences between both
groups as regards the occurrence of complete clinical and/orultrasonographic remission (Table 5). There was no gross
plantar fascia disruption noted after the corticosteroid injec-
tion in both treatment groups. No patients showed recurrence
of symptoms of PF during the 4 week postinjection follow-up.
Figure 1 (A) Longitudinal ultrasonographic image of a 46-year-
old healthy lady volunteer. There is normal plantar fascia with
regular echogenic appearance attached proximally to the calca-
neus. Its thickness is 3.5 mm. (B) Longitudinal ultrasonographic
images of a 50-year-old lady with plantar fasciitis of 24 months
duration. Image (B1) shows evidence of inﬂamed proximal plantar
fascia with thickness of 5 mm and hypoechoic appearance at the
preinjection assessment. Image (B2) shows plantar fascia thickness
of 4 mm with normal echogenicity at the 4 week postinjection
assessment after ultrasound-guided local corticosteroid injection.
This is an indication of complete ultrasonographic remission of
plantar fasciitis in this patient.
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detection of PF, its sensitivity was 100%, speciﬁcity was 100%,
positive predictive value was 100%, and negative predictive
value was 100%. All patients had their sonographic site of
maximal plantar fascia thickness corresponding with their clin-
ical site of maximal tenderness. The majority of the patients
(95.23%) had this site at the attachment of plantar fascia tothe calcaneus except for one patient (4.76%) where this site
was slightly distally located.4. Discussion
The present study aimed to compare the efﬁcacy of US-guided
versus palpation-guided local corticosteroid injection in the
treatment of patients with chronic idiopathic PF.
In the current work, the BMI of about 95.23% of both
treatment groups ranged from overweight to morbid obesity.
This is in agreement with other studies, which reported the
association of PF with obesity [23,24]. This could be due to
the chronic overload and stretch of the plantar fascia resulting
in PF [15].
Findings that support the diagnosis of PF include increased
proximal plantar fascia thickness and areas of hypoechogenic-
ity ultrasonographically [5,6,13,25,26]. Plantar fascia thicken-
ing is a well established feature of PF. In the current study,
the reference cut-off value of plantar fascia thickness by ultra-
sound was 4.1 mm above which all values were considered
abnormal. This is in accordance with other studies [21,25].
Ultrasound has a high accuracy in the diagnosis of PF with
high sensitivity, speciﬁcity, positive predictive value and nega-
tive predictive value. It provides non-invasive objective evi-
dence of inﬂammation. It has several advantages when
compared to scintigraphy. It is relatively safe with no radiation
exposure, quick technique, cheap and widely available. It has a
better spatial resolution for superﬁcial structures in the heel in
patients with PF over MRI [21].
Comparison between the two treatment groups after injec-
tion revealed that there were no statistically signiﬁcant differ-
ences between them regarding the improvement in VAS
assessment of pain, pain and functional components of
Plantar Fasciitis Pain/Disability Scale, decreasing in plantar
fascia thickness and change in the echogenicity of plantar fas-
cia. These results are in agreement with several studies which
assessed both of them [12,13,21]. They reported that there were
no statistically signiﬁcant differences in the outcome measures
following US-guided injection versus palpation-guided injec-
tion in patients with PF [12,13,21].
In the current study, there were statistically signiﬁcant dif-
ferences between the two treatment groups and control group
as regards the PF thickness in the preinjection visit and the two
postinjection follow-up visits. This could be attributed to the
short follow-up period of the current study. The plantar fascia
thickness could need a longer duration to improve till it
reaches its normal values. This could explain why in the pre-
sent study, there was a discrepancy between the frequency of
clinical remission versus ultrasonographic remission in which
some patients had improved ultrasonographically but still
had some pain.
Palpation-guided injection is the approach traditionally
used by rheumatologists and orthopedics [27]. It was accused
of being inaccurate [28,29]. Consequently, patients may require
multiple injections. Additionally, recurrent injections tend to
cause heel fat pad atrophy or fascial rupture [30]. Therefore,
there is a need for monitoring the technique and effects of ster-
oid injection. However in the current study, both techniques
improved PF clinically and ultrasonographically without sta-
tistically signiﬁcant superior results for the ultrasound-guided
injection.
Table 5 Comparison between the two treatment groups as regards the degree of remission of plantar fasciitis assessed clinically
(clinical remission), ultrasonographically (ultrasonographic remission) and both at the 4 week postinjection follow-up visit.
Form of assessment of remission US group (n= 10 patients) PAL group (n= 11 patients) Test of signiﬁcance (X2) P
Clinical remission
Complete remission 4 (40) 3 (27.3) 0.382 0.659
Partial remission 6 (60) 8 (72.7)
Ultrasonographic remission
Complete remission 9 (90) 9 (81.8) 0.286 0.538
Partial remission 1 (10) 2 (18.2)
Clinical and ultrasonographic remission
Complete remission 4 (40) 3 (27.3) 0.382 0.659
Partial remission 6 (60) 8 (72.7)
US group, ultrasound group; PAL group, palpation group; X2, value of Fisher’s Exact test.
Data are reported as number (percentage).
*P is signiﬁcant at 60.05.
Local corticosteroid injection therapy for treatment of plantar fasciitis 129Ultrasound improves the efﬁcacy of local corticosteroid
injection. It improves the accuracy of localization of the site
of steroid injection into the inﬂamed plantar fascia.
Theoretically, US-guided injection has better therapeutic efﬁ-
cacy and fewer side effects than palpation-guided injection
[21]. Objective evaluation of PF response to treatment can be
done by serial US follow-up studies [23]. In the current study,
plantar fascia thickness values have been shown to decrease
signiﬁcantly after corticosteroid injection as early as 2 weeks
and 1 month following treatment. This was also applied for
the plantar fascia echogenicity which improved as well.
Thus, US can be used as an objective measure to assess
response to treatment in PF. Real-time imaging of US is an
advantage for interventional procedures in the musculoskeletal
system as it allows monitoring of the needle during the proce-
dure of injection [27]. Therefore, sonographically guided injec-
tion is shown to be an alternative to palpation-guided injection
because of its high accuracy in guidance and decreasing com-
plication rates [31].
There are no guidelines regarding the type and doses of cor-
ticosteroid used for PF local injection. It was reported that it
varies across discipline and that there were no difference in
the clinical efﬁcacy between different corticosteroid types
[32,33]. Triamcinolone acetonide is one of the intermediates
to long acting glucocorticoids. It was recommended for soft
tissue injections [34]. However, it was considered by some
authors to be inadequate for periarticular injection [35]. It
was assumed that it is associated with greater risk of local com-
plications as heel fat pad atrophy. The current study did not
report any side effect of steroid injection as spontaneous fascia
rupture. This could be due to the short term follow-up period,
proper injection technique, avoidance of repeated weekly injec-
tion and small adequate dose of steroid. These ﬁndings are in
accordance with Tsai et al. [20]. They did not report any local
complications in their follow-up period of 3 months [20].
In the current study, the steroid was not mixed with local
anesthetic. This was also applied in other study [11]. This is
because of the small volume of injected medication. The
injected volume should not exceed 0.5–1 ml at a time. The local
anesthetic agent dilutes the crystalline suspension of corticos-
teroid, so that, it is better diffused within the injected region
to the surrounding tissues [36,37]. Subsequently, local injectionof large volume (corticosteroid and local anesthetic agent) in
PF within the relatively small potential space increases the risk
for local corticosteroid complications as heel fat pad atrophy
and plantar fascia rupture [38]. This is also to assess the occur-
rence of any early side effects of injection as postinjection pain
and ﬂare which occurs in the ﬁrst 24 hours following injection
[22]. In addition, it was reported that no therapeutic advantage
could be detected by adding of a local anesthetic to the corti-
costeroid in the local injection of PF [39]. It was reported that
pharmaceutical manufacturers recommended against mixing
corticosteroid agents with local anesthetic agents because of
the risk of ﬂocculation (clumping) and subsequent precipita-
tion of corticosteroid crystals. However, it was reported that
this is not clinically observed with any frequency [36,37].
The current study had some limitations. First one was the
small number of patients included in the current study. This
was secondary to the following: (i) the inclusion of patients
who were unresponsive to conservative treatment for at least
3 months (chronic cases) and it is reported that conservative
therapy for PF is effective in approximately 90–95% of
patients [3,7,8]; (ii) the wide range of exclusion criteria with
exclusion of patient with bilateral PF; (iii) exclusion of patients
who received a previous corticosteroid injection for PF; (iv) the
preference of patients with chronic PF who were unresponsive
to conservative treatment to seek orthopedic surgery consulta-
tion for their condition; and (v) there were some patients who
refused the participation in the current study. Second one was
the short duration of follow-up period which extended to only
4 weeks. It was reported that local injection of corticosteroid in
the treatment of PF can provide heel pain improvement as
early as 3 weeks to 1 month. This is an evidence of short-
term effectiveness of corticosteroid when given by palpation-
guided injection [11,39]. The short follow-up period is aimed
to assess whether there were short term differences between
both methods of injection for PF. However, short follow-up
period was an opportunity to have no patient lost to follow-
up. Third one, there was no control group with placebo injec-
tion included in the current study. It was not ethical to do an
invasive maneuver using a placebo drug to patients with
chronic PF. Fourth one, the study included only women in
both treatment groups. It was reported that PF is common
among women more than men [3]. Men usually utilize the
130 E.K.A. Saba, S.M. El-Sherifhealth services provided by the health insurance which is
related to their employment.
The current study recommends the following: (i) corticos-
teroid injection for PF is an effective method of treatment
for chronic idiopathic PF; (ii) US is sensitive and speciﬁc in
diagnosing PF; (iii) palpation-guided injection should be used
wherever there are no available ultrasonography for
US-guided injection; and (iv) US is a useful tool for assessment
of improvement of PF in response to treatment.
In conclusion, both US-guided and palpation-guided local
corticosteroid injections were effective and successful in
treatment of PF. Both techniques improved PF clinically and
ultrasonographically without statistically signiﬁcant superior
results for the ultrasound-guided injection. US is useful for
the diagnosis and assessment of PF, as well as, it provides a
useful tool for the assessment of improvement of PF.Conﬂict of interest
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